All lobbying filings

INSULET CORPORATION

INSULET CORPORATION filed a Q3 report for INSULET CORPORATION on October 20, 2026.

Lobbying for INSULET CORPORATION

All filings by INSULET CORPORATION · Everything INSULET CORPORATION has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 20, 2026

Expenses

$140,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

Massachusetts

Official filing document

Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Health Issues

Issues related to the disease of diabetes, diabetes therapies, automated insulin delivery devices, and management of the disease of diabetes. Issues related to medical devices and medical device technologies. Issues related to Pharmacy Benefit Manager (PBM) reform proposals, PBM transparency and potential PBM proposals related to talks of future budget reconciliation and/or year end package. Issues related to the DIABETES Act. Issues related to artificial intelligence (AI) and predictive algorithms in medical devices and medical device technology. Issues related to tariffs and trade and the Sec. 232 Tariff investigation related to Medical Devices. Issues related to Local Coverage Determination revisions specifically in pathways for Continuous Glucose Monitors (CGM). Issues related to National Coverage Determination revisions specifically in reference to durable infusion insulin pumps. Issues related to Prior Authorizations in Medicare Advantage plans. Issues related to support of Improving Seniors' Timely Access to Care Act. Issues related to CMS finalized rule, DMEPOS Home Health Rule. Issues related to expansion of Competitive Bidding Program and implementation of CMS finalized rule relating to DMEPOS Home Health Rule. Issues related to combatting fraud, waste and abuse in the Medicare program - specifically related to the way continuous glucose monitors are billed in Medicare and potential solutions to vet durable medical equipment vendors at CMS. Issues related to wearable health care devices.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.